• Home
  • News
  • 2017
  • Reig Jofre launches Complidermol 5α PLUS, a dietary...

Reig Jofre launches Complidermol 5α PLUS, a dietary supplement for the treatment of female androgenetic alopecia

Wednesday, 15 February 2017.

  • Complidermol 5α PLUS is the first dietary supplement for female androgenetic alopecia which, thanks to its novel formulation developed by the R&D team at Reig Jofre, tackles not only the known hormonal factor, but also the oxidative and inflammatory factors, new pathophysiological factors identified as causes of this condition.
  • Female androgenetic alopecia currently affects around 40% of women over 50, with significant impact on their psychological wellbeing and quality of life and accounting for 3% to 8% of first appointments with dermatologists.
  • Complidermol 5α PLUS results from combining two key strategic areas for Reig Jofre – dermatology and dietary supplements – where the company is widening its approach to healthcare through prevention.
  • Reig Jofre is at the forefront of the Spanish market in the treatment for this condition, where it has over ten years’ experience in development and marketing.

Pharmaceutical company Reig Jofre launches Complidermol 5α PLUS, a dietary supplement offering a more comprehensive clinical approach to female androgenetic alopecia (FAA), which currently affects around 40% of women over 50.

Reig Jofre has over ten years’ experience in the treatment of female androgenetic alopecia and is market leader in Spain. Complidermol 5α PLUS results from combining two key strategic areas for Reig Jofre – dermatology and dietary supplements – where the company is widening its approach to healthcare through prevention.

Following an in-depth review of the scientific literature on this condition, experts have concluded that, in addition to the genetic and hormonal factors known and treated to date in FPB, there are also other factors which can be considered responsible for this condition, such as oxidative stress and micro-inflammation in the affected area.

Complidermol 5α PLUS has an increased effect on the known hormonal factor and in addition treats these newly-identified pathophysiological factors, which play a part in the shrinkage of hair follicles characteristic of this condition.

Complidermol 5α PLUS has been developed to slow down the progression of FAA, revitalise the hair follicle and lengthen the anagen phase of hair growth. The aim is to improve hair quality and the quality of life of women suffering from this condition.

Download the full document (PDF)

This site uses only technical third party cookies to provide better service, when browsing this website you agree to its use. See ourlegal advice. Agree

DMC Firewall is developed by Dean Marshall Consultancy Ltd